Ptc Therapeutics (PTCT) Operating Expenses (2012 - 2026)

Ptc Therapeutics' Operating Expenses history runs 15 years deep, the most recent figure standing at $227.6 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 10.55% year-over-year to $227.6 million; the TTM figure through Mar 2026 stood at $885.4 million (down 16.44% YoY), while the FY2025 annual figure was $863.7 million, down 22.14% from the prior year.
• Operating Expenses was $227.6 million for Q1 2026 at Ptc Therapeutics, down from $236.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $423.4 million in Q2 2023 to a low of $205.9 million in Q1 2025.
• Historically, Operating Expenses has averaged $277.9 million across 5 years, with a median of $255.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 64.16% in 2023, then slumped 46.4% in 2024.
• A 5-year view of Operating Expenses shows it stood at $367.8 million in 2022, then slipped by 18.09% to $301.2 million in 2023, then grew by 24.67% to $375.6 million in 2024, then tumbled by 37.15% to $236.0 million in 2025, then retreated by 3.57% to $227.6 million in 2026.
• The last three Operating Expenses figures came in at $227.6 million (Q1 2026), $236.0 million (Q4 2025), and $208.0 million (Q3 2025), per Business Quant data.